Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Hydrops MR Imaging: Comparison in Contralateral Clinically Unaffected Ears

BACKGROUND AND PURPOSE: Hydrops MR imaging, performed 4 hours after IV gadolinium administration, requires sufficient contrast-agent accumulation in the perilymph to delineate the nonenhancing endolymphatic spaces. The higher relaxivity of gadopiclenol may reduce gadolinium exposure while preserving perilymphatic enhancement and anatomic detail. Clinically unaffected contralateral reference ears provide a standardized reference that minimizes disease-related confounding. We compared half-dose gadopiclenol (0.05 mmol/kg; half the gadolinium dose) with full-dose gadobutrol (0.1 mmol/kg) for hydrops MR imaging. MATERIALS AND METHODS: This retrospective study reviewed 90 consecutive patients referred for hydrops MR imaging. Forty-five received gadobutrol (1.0 mmol/mL; 0.1 mmol/kg), and 45 received gadopiclenol (0.5 mmol/mL; 0.05 mmol/kg). Two experienced head and neck radiologists, blinded to clinical findings and contrast agent, independently evaluated the clinically unaffected reference ear. Quantitative endpoints were the signal intensity ratio (SIR) and reference-normalized contrast (RNC); qualitative endpoints were separate delineation of the saccule and utricle and visibility of the 3 semicircular canal ampullae. The prespecified noninferiority margin was 0.5 units, with a sensitivity analysis using 0.25 units. RESULTS: Seventy-one patients were included: 37 received gadopiclenol and 34 received gadobutrol. Nineteen were excluded because of motion degradation, suspected bilateral disease, or abnormal audiometric or MR imaging findings in the reference ear. Mean reader-averaged SIR was 8.15 (SD, 1.51) with gadopiclenol and 7.59 (SD, 1.40) with gadobutrol, yielding a mean difference of 0.56 (95% CI, -0.13 to 1.25). Mean reader-averaged RNC was 7.66 (SD, 1.56) and 6.97 (SD, 1.37), respectively, yielding a mean difference of 0.69 (95% CI, 0.00 to 1.39). Both lower confidence limits exceeded the noninferiority boundary of -0.5; noninferiority was maintained using -0.25. Interreader reliability was excellent for SIR (ICC, 0.915; 95% CI, 0.868-0.946) and RNC (ICC, 0.925; 95% CI, 0.882-0.952). Qualitative assessments showed no significant between-group differences. Where estimable, Cohen κ ranged from 0.66 to 1.00; observed agreement was 97.2%-100% for features with nonestimable κ. CONCLUSIONS: In clinically unaffected reference ears, gadopiclenol at 0.05 mmol/kg provides quantitative perilymphatic enhancement noninferior to that of gadobutrol at 0.1 mmol/kg, with comparable qualitative anatomic delineation. Higher-relaxivity gadopiclenol may therefore reduce gadolinium exposure without compromising reference-ear image quality.

Authors

Institutions

Publication Details

Journal
American Journal of Neuroradiology
Published
2026-11-17
DOI
https://doi.org/10.3174/ajnr.a9719
Primary Topic
Vestibular and auditory disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Hydrops MR Imaging: Comparison in Contralateral Clinically Unaffected Ears

Anja Bernaerts, Kathleen Dhont, F. Deckers, Andrzej J. Zarowski et al.
1 links
American Journal of Neuroradiology
Vestibular and auditory disorders
article

Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Hydrops MR Imaging: Comparison in Contralateral Clinically Unaffected Ears

Anja Bernaerts, Kathleen Dhont, F. Deckers, Andrzej J. Zarowski, Cathérine Blaivie, Caroline Venstermans, Joost van Dinther, Floris L. Wuyts, Bert De Foer
article en

Abstract

BACKGROUND AND PURPOSE: Hydrops MR imaging, performed 4 hours after IV gadolinium administration, requires sufficient contrast-agent accumulation in the perilymph to delineate the nonenhancing endolymphatic spaces. The higher relaxivity of gadopiclenol may reduce gadolinium exposure while preserving perilymphatic enhancement and anatomic detail. Clinically unaffected contralateral reference ears provide a standardized reference that minimizes disease-related confounding. We compared half-dose gadopiclenol (0.05 mmol/kg; half the gadolinium dose) with full-dose gadobutrol (0.1 mmol/kg) for hydrops MR imaging. MATERIALS AND METHODS: This retrospective study reviewed 90 consecutive patients referred for hydrops MR imaging. Forty-five received gadobutrol (1.0 mmol/mL; 0.1 mmol/kg), and 45 received gadopiclenol (0.5 mmol/mL; 0.05 mmol/kg). Two experienced head and neck radiologists, blinded to clinical findings and contrast agent, independently evaluated the clinically unaffected reference ear. Quantitative endpoints were the signal intensity ratio (SIR) and reference-normalized contrast (RNC); qualitative endpoints were separate delineation of the saccule and utricle and visibility of the 3 semicircular canal ampullae. The prespecified noninferiority margin was 0.5 units, with a sensitivity analysis using 0.25 units. RESULTS: Seventy-one patients were included: 37 received gadopiclenol and 34 received gadobutrol. Nineteen were excluded because of motion degradation, suspected bilateral disease, or abnormal audiometric or MR imaging findings in the reference ear. Mean reader-averaged SIR was 8.15 (SD, 1.51) with gadopiclenol and 7.59 (SD, 1.40) with gadobutrol, yielding a mean difference of 0.56 (95% CI, -0.13 to 1.25). Mean reader-averaged RNC was 7.66 (SD, 1.56) and 6.97 (SD, 1.37), respectively, yielding a mean difference of 0.69 (95% CI, 0.00 to 1.39). Both lower confidence limits exceeded the noninferiority boundary of -0.5; noninferiority was maintained using -0.25. Interreader reliability was excellent for SIR (ICC, 0.915; 95% CI, 0.868-0.946) and RNC (ICC, 0.925; 95% CI, 0.882-0.952). Qualitative assessments showed no significant between-group differences. Where estimable, Cohen κ ranged from 0.66 to 1.00; observed agreement was 97.2%-100% for features with nonestimable κ. CONCLUSIONS: In clinically unaffected reference ears, gadopiclenol at 0.05 mmol/kg provides quantitative perilymphatic enhancement noninferior to that of gadobutrol at 0.1 mmol/kg, with comparable qualitative anatomic delineation. Higher-relaxivity gadopiclenol may therefore reduce gadolinium exposure without compromising reference-ear image quality.

American Journal of Neuroradiology
University of Antwerp (BE), GZA Ziekenhuizen Campus Sint-Augustinus (BE), Ziekenhuis aan de Stroom (BE)
Good health and well-being
Vestibular and auditory disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon